Impax Asset Management LTD increased its stake in shares of Danaher Corporation (NYSE:DHR) by 13.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,279,220 shares of the conglomerate’s stock after buying an additional 148,526 shares during the period. Danaher Corporation accounts for 4.5% of Impax Asset Management LTD’s investment portfolio, making the stock its 5th largest position. Impax Asset Management LTD owned 0.18% of Danaher Corporation worth $109,412,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of DHR. FMR LLC boosted its position in shares of Danaher Corporation by 0.3% in the first quarter. FMR LLC now owns 19,441,167 shares of the conglomerate’s stock valued at $1,662,803,000 after buying an additional 53,429 shares in the last quarter. Parnassus Investments CA boosted its position in shares of Danaher Corporation by 15.3% in the first quarter. Parnassus Investments CA now owns 8,622,528 shares of the conglomerate’s stock valued at $712,738,000 after buying an additional 1,143,284 shares in the last quarter. Bank of New York Mellon Corp increased its position in Danaher Corporation by 0.7% in the first quarter. Bank of New York Mellon Corp now owns 7,645,818 shares of the conglomerate’s stock valued at $653,946,000 after buying an additional 50,673 shares during the last quarter. Flossbach Von Storch AG increased its position in Danaher Corporation by 6.2% in the first quarter. Flossbach Von Storch AG now owns 3,996,209 shares of the conglomerate’s stock valued at $341,796,000 after buying an additional 234,770 shares during the last quarter. Finally, First Manhattan Co. increased its position in Danaher Corporation by 0.8% in the first quarter. First Manhattan Co. now owns 2,932,760 shares of the conglomerate’s stock valued at $229,899,000 after buying an additional 22,098 shares during the last quarter. 76.56% of the stock is owned by institutional investors and hedge funds.
Danaher Corporation (NYSE DHR) traded up 0.67% during midday trading on Friday, hitting $79.82. 2,433,944 shares of the company traded hands. The stock’s 50-day moving average price is $82.89 and its 200 day moving average price is $84.21. The company has a market capitalization of $55.45 billion, a price-to-earnings ratio of 25.48 and a beta of 1.03. Danaher Corporation has a 12-month low of $75.71 and a 12-month high of $88.01.
Danaher Corporation (NYSE:DHR) last posted its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.02. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The company had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.50 billion. During the same quarter in the previous year, the firm earned $0.90 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities analysts forecast that Danaher Corporation will post $3.95 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Danaher Corporation (NYSE:DHR) Stake Boosted by Impax Asset Management LTD” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.com-unik.info/2017/08/11/impax-asset-management-ltd-buys-148526-shares-of-danaher-corporation-nysedhr-updated.html.
A number of equities research analysts have recently commented on the company. Royal Bank Of Canada restated a “sector perform” rating and set a $88.00 price objective (down previously from $89.00) on shares of Danaher Corporation in a research note on Friday, April 21st. BidaskClub cut Danaher Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut Danaher Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. Citigroup Inc. set a $96.00 price objective on Danaher Corporation and gave the company a “buy” rating in a research note on Friday, July 21st. Finally, Janney Montgomery Scott cut Danaher Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Danaher Corporation has an average rating of “Buy” and an average price target of $91.76.
In related news, SVP Angela S. Lalor sold 10,815 shares of Danaher Corporation stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $84.16, for a total transaction of $910,190.40. Following the completion of the sale, the senior vice president now owns 39,020 shares of the company’s stock, valued at $3,283,923.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Linda P. Hefner sold 10,578 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $83.03, for a total value of $878,291.34. Following the completion of the transaction, the director now directly owns 42,151 shares of the company’s stock, valued at $3,499,797.53. The disclosure for this sale can be found here. Insiders have sold 38,623 shares of company stock worth $3,206,426 in the last 90 days. Insiders own 12.20% of the company’s stock.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
What are top analysts saying about Danaher Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Danaher Corporation and related companies.